491 related articles for article (PubMed ID: 8628874)
1. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution.
Kurhanewicz J; Vigneron DB; Hricak H; Narayan P; Carroll P; Nelson SJ
Radiology; 1996 Mar; 198(3):795-805. PubMed ID: 8628874
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging.
Kurhanewicz J; Vigneron DB; Hricak H; Parivar F; Nelson SJ; Shinohara K; Carroll PR
Radiology; 1996 Aug; 200(2):489-96. PubMed ID: 8685346
[TBL] [Abstract][Full Text] [Related]
3. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy.
Kurhanewicz J; Vigneron DB; Nelson SJ; Hricak H; MacDonald JM; Konety B; Narayan P
Urology; 1995 Mar; 45(3):459-66. PubMed ID: 7533458
[TBL] [Abstract][Full Text] [Related]
4. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer.
van Dorsten FA; van der Graaf M; Engelbrecht MR; van Leenders GJ; Verhofstad A; Rijpkema M; de la Rosette JJ; Barentsz JO; Heerschap A
J Magn Reson Imaging; 2004 Aug; 20(2):279-87. PubMed ID: 15269954
[TBL] [Abstract][Full Text] [Related]
5. 1H-MRSI of prostate cancer: the relationship between metabolite ratio and tumor proliferation.
Wang XZ; Wang B; Gao ZQ; Liu JG; Liu ZQ; Niu QL; Sun ZK; Yuan YX
Eur J Radiol; 2010 Feb; 73(2):345-51. PubMed ID: 19070978
[TBL] [Abstract][Full Text] [Related]
6. High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features--initial experience.
Hom JJ; Coakley FV; Simko JP; Lu Y; Qayyum A; Westphalen AC; Schmitt LD; Carroll PR; Kurhanewicz J
Radiology; 2007 Feb; 242(2):483-9. PubMed ID: 17179396
[TBL] [Abstract][Full Text] [Related]
7. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue.
Heerschap A; Jager GJ; van der Graaf M; Barentsz JO; de la Rosette JJ; Oosterhof GO; Ruijter ET; Ruijs SH
Anticancer Res; 1997; 17(3A):1455-60. PubMed ID: 9179183
[TBL] [Abstract][Full Text] [Related]
8. Pathologic characterization of human prostate tissue with proton MR spectroscopy.
Swindle P; McCredie S; Russell P; Himmelreich U; Khadra M; Lean C; Mountford C
Radiology; 2003 Jul; 228(1):144-51. PubMed ID: 12832578
[TBL] [Abstract][Full Text] [Related]
9. Combined morphological, [1H]-MR spectroscopic and contrast-enhanced imaging of human prostate cancer with a 3-Tesla scanner: preliminary experience.
Carlani M; Mancino S; Bonanno E; Finazzi Agrò E; Simonetti G
Radiol Med; 2008 Aug; 113(5):670-88. PubMed ID: 18493829
[TBL] [Abstract][Full Text] [Related]
10. [Spectroscopic imaging (1H-2D-CSI) of the prostate: sequence optimization and correlation with histopathological results].
Stanka M; Eltze E; Semjonow A; Sievert KD; Maier A; Pfleiderer B
Rofo; 2000 Jul; 172(7):623-9. PubMed ID: 10962989
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings.
Mazaheri Y; Shukla-Dave A; Hricak H; Fine SW; Zhang J; Inurrigarro G; Moskowitz CS; Ishill NM; Reuter VE; Touijer K; Zakian KL; Koutcher JA
Radiology; 2008 Feb; 246(2):480-8. PubMed ID: 18227542
[TBL] [Abstract][Full Text] [Related]
12. High-resolution 3D MR spectroscopic imaging of the prostate at 3 T with the MLEV-PRESS sequence.
Chen AP; Cunningham CH; Kurhanewicz J; Xu D; Hurd RE; Pauly JM; Carvajal L; Karpodinis K; Vigneron DB
Magn Reson Imaging; 2006 Sep; 24(7):825-32. PubMed ID: 16916699
[TBL] [Abstract][Full Text] [Related]
13. Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging.
Kaji Y; Kurhanewicz J; Hricak H; Sokolov DL; Huang LR; Nelson SJ; Vigneron DB
Radiology; 1998 Mar; 206(3):785-90. PubMed ID: 9494502
[TBL] [Abstract][Full Text] [Related]
14. Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging--initial results.
Zakian KL; Eberhardt S; Hricak H; Shukla-Dave A; Kleinman S; Muruganandham M; Sircar K; Kattan MW; Reuter VE; Scardino PT; Koutcher JA
Radiology; 2003 Oct; 229(1):241-7. PubMed ID: 12920178
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study.
Scheidler J; Hricak H; Vigneron DB; Yu KK; Sokolov DL; Huang LR; Zaloudek CJ; Nelson SJ; Carroll PR; Kurhanewicz J
Radiology; 1999 Nov; 213(2):473-80. PubMed ID: 10551229
[TBL] [Abstract][Full Text] [Related]
16. MRI spectroscopy in screening of prostate cancer.
Goeb K; Engehausen DG; Krause FS; Hollenbach HP; Niedobitek G; Buettner M; Frangou P; Engelhard K
Anticancer Res; 2007; 27(1B):687-93. PubMed ID: 17348461
[TBL] [Abstract][Full Text] [Related]
17. Peripheral zone prostate cancer. Pre-treatment evaluation with MR and 3D ¹H MR spectroscopic imaging: correlation with pathologic findings.
Giusti S; Caramella D; Fruzzetti E; Lazzereschi M; Tognetti A; Bartolozzi C
Abdom Imaging; 2010 Dec; 35(6):757-63. PubMed ID: 19756851
[TBL] [Abstract][Full Text] [Related]
18. Proton MR spectroscopy of the prostate.
Mueller-Lisse UG; Scherr MK
Eur J Radiol; 2007 Sep; 63(3):351-60. PubMed ID: 17709223
[TBL] [Abstract][Full Text] [Related]
19. 2D JPRESS of human prostates using an endorectal receiver coil.
Yue K; Marumoto A; Binesh N; Thomas MA
Magn Reson Med; 2002 Jun; 47(6):1059-64. PubMed ID: 12111951
[TBL] [Abstract][Full Text] [Related]
20. Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathology.
Selnæs KM; Heerschap A; Jensen LR; Tessem MB; Schweder GJ; Goa PE; Viset T; Angelsen A; Gribbestad IS
Invest Radiol; 2012 Nov; 47(11):624-33. PubMed ID: 23011187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
